Search
Back

Abemaciclib

CAS 1231929-97-7
Abemaciclib

General Information

Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4  and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. Abemaciclib is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with Fulvestrant. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.


About the API

Technology Synthetic
Molecular Formula C28H35FO7
Therapeutic category Oncology
Available formulations Oral Solid
Regulations
  • Japan DMF
  • Korea DMF
  • US DMF

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.